Canadian Cancer Trials Group Bulletins

General


Canadian Cancer Trials Group CO.17 Highlighted in NCI Bulletin

The current edition of the NCI Bulletin is highlighting three colorectal cancer trials, including CO.17, that support gene testing for two drugs -- cetuximab and panitumumab. These new studies add to the growing evidence that patients with colorectal cancer should have their tumors tested for genetic mutations prior to starting therapy with cetuximab (Erbitux) or panitumumab (Vectibix). Tumors with certain mutations are unlikely to respond to the drugs, and these patients should be spared the expense and side effects of the medications, the findings suggest.

To read the entire article, click here ... http://www.cancer.gov/ncicancerbulletin/NCI_Cancer_Bulletin_110408/page5.